Clinical Trials
Eisai: Updated Analysis of Phase Ib/II Study of Eribulin and Pembrolizumab Combination Regimen
Eisai Co .Ltd. announced that a presentation on the updated analysis of a global Phase Ib/II clinical study (ENHANCE 1 / Study 218) of its in-house discovered and developed anticancer agent eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product...
Clinical Trials
Plasticell and Anthony Nolan to partner in clinical trials of ex vivo expanded cord blood stem cells
Plasticell, a developer of innovative stem cell technologies and cell therapies announced it will collaborate with Anthony Nolan, a leading research organisation dedicated to saving the lives of people with blood cancers, to progress clinical development of Plasticell’s ex...
Clinical Trials
Inovio Announces Analysis Of VGX-3100 Phase 2b Data
Inovio Pharmaceuticals, Inc announced that post-hoc analysis of data generated from its phase 2b trial of VGX-3100 identified immune correlates and biomarker signatures predictive of treatment success. VGX-3100, Inovio’s lead product now in a pivotal phase...
Clinical Trials
OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi® in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
OSE Immunotherapeutics announces that the Independent Data Monitoring Committee (IDMC) has recommended to the trial’s steering committee that accrual of the Tedopi® Phase 3 trial for the treatment of advanced non-small cell lung cancer (NSCLC) could resume with a...
Clinical Trials
CRF Health’s TrialMax Touch® Selected by Leading Specialty Pharmaceutical Company for Pediatric Rare Disease Phase II Study
CRF Health, the leading global provider of patient-centered eSource technology and service solutions for the life sciences industry, has been selected by a leading specialty pharmaceutical company for its latest pediatric rare disease Phase II study. ...
Clinical Trials
Cmed to Demonstrate how encapsia® Transforms Clinical Trial Data Management, Capture and Reporting at Leading Oncology Meetings
Cmed, an oncology focused, innovative technology-led CRO, announced that it will showcase its encapsia® clinical data suite at two leading oncology meetings, Clinical Operations in Oncology Trials Europe, taking place 5-6 December in Munich, Germany, and the ASH Annual...
Articles
Direct-to-Patient Solutions Assuring Patient Participation and Retention in Clinical Trials
The average cost of bringing a new drug to market is $2.6 billion, according to a 2014 report published by Tufts Center for the Study of Drug Development. This is a rise of 145%, adjusted for inflation, compared to just...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.